SINGAPORE’S LARGEST AND LEADING CO-WORKING LABORATORY & OFFICE SPACE

Daphne is an experienced investor and company builder, with over a decade of experience in real estate, biotech, and investment banking. She is the founder and CEO of NSG BioLabs, Singapore’s largest and leading biotech co-working laboratory and office space. She led the entire setup of NSG, including financing, operational setup, and recruited a team of internationally renowned professors, investors, and biotech executives to advise NSG and its companies.

She was one of the initial shareholders and co-founders of the Singapore- and US-based Engine Biosciences and previously served as a board director and head of finance and operations in its critical early days before and after venture financing. She continues to serve as an advisor to Engine Biosciences.

She currently also serves as Chief Investment Officer of D3 Capital and previously worked at Goldman Sachs and HSBC in the Investment Banking Division in Hong Kong and Singapore.

At D3, she has executed and overseen a number of multi-million investments in real estate and natural resources across Asia and USA. She also serves as a board director at selected portfolio companies. In 2013, she was a co-founder and investor in the 3.6M sq. ft. Golden City integrated real estate development in Yangon, Myanmar and helped drive the successful sale of the company at a valuation of US$110 million in 2016 achieving triple digit IRR for D3.

Daphne received her master’s from Stanford University’s School of Engineering and her bachelor’s from Purdue University (highest honors), and she is currently pursuing her master’s in biotechnology at Johns Hopkins University.

Trained as a biomedical engineer, Cheryl’s personal mission is to identify promising technologies that address unmet clinical needs and work directly with founders during the venture building process. She was a former Venture Partner at VentureHealth, a Silicon Valley-based healthcare fund, where she coordinated portfolio companies’ growth strategy in the Asia Pacific. Cheryl previously co-founded a mobile health company that facilitates the care of Alzheimer’s patients, which was successfully acquired in 2012 and led to her selection as one of Canada’s Next 36. She currently serves as a Board Member of Rootpath and HiFiBio Therapeutics.

Cheryl earned her joint PhD degree in Medical Engineering and Medical Physics from MIT and Harvard Medical School. Her research in building synthetic gene circuits and molecular systems have lead to publications in Science and Nature journals. Cheryl received her B.A.Sc. in Engineering Science and Biomedical Engineer from the University of Toronto.